Halopemide
Based on 1 publication(s) in Google Scholar
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent.
For research use only. We do not sell to patients.
- Purity: 99.65%
- CAS No.: 59831-65-1
- Formula: C21H22ClFN4O2
- Molecular Weight:416.88
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Exosomes Compound Library
HY-L072
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Lipid Metabolism Compound Library
HY-L091
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Dopamine Receptor Compound Library
HY-L165
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
-
GPCR/G Protein Compound Library
HY-L006
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) Halopemide
More
Customer Validation & Images
-
Flow Cytometry
All Phospholipase Isoforms
MoreAll Dopamine Receptor Isoforms
More
Biological Activity
|
D1 Receptor |
D2 Receptor |
PLD1 220 nM (IC50) |
PLD2 310 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-1 | IC50 |
21 nM
Compound: 8
|
Inhibition of PLD1 in human Calu-1 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis
Inhibition of PLD1 in human Calu-1 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis
|
[PMID: 19136975] |
| Calu-1 | IC50 |
21 nM
Compound: 1
|
Inhibition of human PLD1 in Calu1 cells
Inhibition of human PLD1 in Calu1 cells
|
[PMID: 19268584] |
| HEK293 | IC50 |
300 nM
Compound: 1
|
Inhibition of GFP-labelled human PLD2 HEK293 cells
Inhibition of GFP-labelled human PLD2 HEK293 cells
|
[PMID: 19268584] |
| HEK293 | IC50 |
6500 nM
Compound: 8
|
Inhibition of GFP-tagged human PLD2 expressed in human HEK293 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis
Inhibition of GFP-tagged human PLD2 expressed in human HEK293 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis
|
[PMID: 19136975] |
Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 59831-65-1
-
Appearance Solid
-
Molecular Weight 416.88
-
Formula C21H22ClFN4O2
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CC=C(C=C1)F)NCCN2CCC(CC2)N3C4=CC=C(C=C4NC3=O)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages. [Abstract]2025 Nov;10(11):2949-2965. PMID: 41073667
Halopemide purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2949-2965. [Abstract]
Naive CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 and TGFβ for 3 days and treated with DMSO or treated with Linoleic acid (100 μM) for 48 h. Linoleic acid promotes Ca2+-dependent CTLA-4 surface trafficking.
Solvent & Solubility
DMSO : 41.67 mg/mL (99.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [Content Brief]
[2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. [Content Brief]
[3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3988 mL | 11.9939 mL | 23.9877 mL | 59.9693 mL |
| 5 mM | 0.4798 mL | 2.3988 mL | 4.7975 mL | 11.9939 mL | |
| 10 mM | 0.2399 mL | 1.1994 mL | 2.3988 mL | 5.9969 mL | |
| 15 mM | 0.1599 mL | 0.7996 mL | 1.5992 mL | 3.9980 mL | |
| 20 mM | 0.1199 mL | 0.5997 mL | 1.1994 mL | 2.9985 mL | |
| 25 mM | 0.0960 mL | 0.4798 mL | 0.9595 mL | 2.3988 mL | |
| 30 mM | 0.0800 mL | 0.3998 mL | 0.7996 mL | 1.9990 mL | |
| 40 mM | 0.0600 mL | 0.2998 mL | 0.5997 mL | 1.4992 mL | |
| 50 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1994 mL | |
| 60 mM | 0.0400 mL | 0.1999 mL | 0.3998 mL | 0.9995 mL | |
| 80 mM | 0.0300 mL | 0.1499 mL | 0.2998 mL | 0.7496 mL |
Halopemide Related Classifications
HY-119093 Related Classifications
Powered by Bioz